Abeona Therapeutics (NASDAQ:ABEO) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note published on Tuesday.

Other analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Price Performance

ABEO stock opened at $5.86 on Tuesday. The firm has a 50 day moving average of $5.72 and a 200-day moving average of $5.74. The firm has a market capitalization of $254.73 million, a P/E ratio of -2.18 and a beta of 1.43. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors have recently modified their holdings of the company. abrdn plc boosted its stake in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after buying an additional 200,647 shares in the last quarter. Western Standard LLC lifted its holdings in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 21.7% in the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after purchasing an additional 83,050 shares in the last quarter. Rosalind Advisors Inc. grew its holdings in shares of Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after purchasing an additional 82,000 shares during the last quarter. Finally, Citigroup Inc. raised its position in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the period. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.